Congress Asset Management Co. Has $157.32 Million Position in Boston Scientific Corporation $BSX

Congress Asset Management Co. cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 2.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,649,958 shares of the medical equipment provider’s stock after selling 34,119 shares during the quarter. Boston Scientific comprises 1.1% of Congress Asset Management Co.’s portfolio, making the stock its 17th largest position. Congress Asset Management Co. owned approximately 0.11% of Boston Scientific worth $157,323,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BSX. Assenagon Asset Management S.A. lifted its stake in shares of Boston Scientific by 47.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,306,176 shares of the medical equipment provider’s stock valued at $410,594,000 after purchasing an additional 1,391,559 shares during the period. Westview Management dba Westview Investment Advisors acquired a new stake in shares of Boston Scientific during the fourth quarter worth $2,363,000. 180 Wealth Advisors LLC grew its stake in shares of Boston Scientific by 12.2% during the fourth quarter. 180 Wealth Advisors LLC now owns 6,245 shares of the medical equipment provider’s stock worth $595,000 after purchasing an additional 681 shares during the period. Gradient Investments LLC increased its holdings in Boston Scientific by 1.7% in the fourth quarter. Gradient Investments LLC now owns 234,261 shares of the medical equipment provider’s stock valued at $22,337,000 after purchasing an additional 3,889 shares during the last quarter. Finally, Regent Peak Wealth Advisors LLC bought a new stake in Boston Scientific in the fourth quarter valued at about $215,000. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BSX. Evercore reduced their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Stifel Nicolaus lowered their price target on Boston Scientific from $110.00 to $90.00 and set a “buy” rating for the company in a research note on Friday. Morgan Stanley reduced their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Robert W. Baird decreased their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Finally, The Goldman Sachs Group set a $99.00 target price on shares of Boston Scientific in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $106.27.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.50% of the stock is owned by company insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham & Company reiterated a “Buy” rating on BSX, reinforcing institutional support for the shares amid the post-earnings pullback; this helps underpin demand from investors looking for growth exposure in medical devices. Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Several market write-ups argue the pullback could be a buying opportunity given solid recent fundamentals (beat on adjusted EPS, strong free cash flow, growth in EP and Watchman) and potential catalysts such as Champion-AF trial results and the planned Penumbra acquisition — but these are contingent on upcoming clinical and integration outcomes. Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback?
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for a securities class action covering purchases between July 23, 2025 and Feb 3, 2026; they remind investors of a May 4, 2026 lead-plaintiff deadline — this increases legal overhang and potential litigation costs/settlement risk. ROSEN – Class Action Notice Robbins LLP – Class Action Alert Faruqi & Faruqi – Class Action Notice
• Negative Sentiment: MassDevice reports alleged long-running pacemaker battery problems — product reliability and potential recalls or regulatory scrutiny could materially affect device sales and margins if issues are confirmed and widespread. Boston Scientific has reportedly had pacemaker battery problems for years
• Negative Sentiment: Stifel cut its price target on BSX to $90, signaling some analyst caution and reduced near-term upside expectations even where ratings remain constructive — this can weigh on sentiment and caps potential rebound momentum. Stifel Nicolaus Cuts Boston Scientific Price Target to $90

Boston Scientific Stock Up 0.1%

Shares of Boston Scientific stock opened at $69.54 on Tuesday. The company has a market capitalization of $103.34 billion, a P/E ratio of 35.84, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The business has a 50-day moving average of $79.22 and a two-hundred day moving average of $91.68. Boston Scientific Corporation has a 1 year low of $67.56 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the firm earned $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.